| Identification | Back Directory | [Name]
β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI) | [CAS]
647834-15-9 | [Synonyms]
Atigliflozin
β-D-Glucopyranoside, 2-[(4-methoxyphenyl)methyl]-3-thienyl
β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI)
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methyl]thiophen-3-yl]oxyoxane-3,4,5-triol | [Molecular Formula]
C18H22O7S | [MDL Number]
MFCD19443710 | [MOL File]
647834-15-9.mol | [Molecular Weight]
382.43 |
| Hazard Information | Back Directory | [Uses]
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus[1]. | [in vivo]
AVE2268 (1-300 mg/kg, p.o.) causes a dose-dependent increase of urinary glucose excretion (UGE) in mice and rats[2].
AVE2268 (10-100 mg/kg, p.o.) dose-dependently decreases blood glucose excursions after glucose (i.p. or p.o.) administration in mice[2].
| [IC 50]
hSGLT2: 10 nM (IC50); hSGLT1: 8.2 μM (IC50) | [References]
[1] Schudok M, et al. The magic of small structure differences in a sodium-glucose cotransporter drug discovery project-14 C-labelled drug candidates in a key-differentiating study. J Labelled Comp Radiopharm. 2021 Feb;64(2):73-76. DOI:10.1002/jlcr.3869
[2] Bickel M, et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80. DOI:10.1055/s-0031-1296559 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|